Goldenrod Therapeutics

Private

Houston, Texas-based precision therapeutics company advancing 11h, an orally bioavailable brain-penetrant PDE4 inhibitor. First target: Friedreich's Ataxia. Then broader neurodegenerative and neuroinflammatory indications. Technology in-licensed from University of Nebraska Medical Center. Founded 2023.

Founders Dev Chatterjee

CEO Dev Chatterjee

Company

Founded

2023

Headquarters

Houston, USA

Financials

Total Funding

$7M

Sectors

Healthtech Biotech

goldenrodtherapeutics.com

Funding History

1 round

Seed Jun 8, 2026

$7M

Ataxia Ventures (Lead) Fannin Partners

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.